Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc. (PTGX) Revenue
Annual & quarterly revenue history · segment & region breakdown
PTGX · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsProtagonist Therapeutics, Inc. trailing twelve-month (TTM) revenue is $0.07B, a decrease of 89.41% year-over-year from $0.05B in FY2025.
Revenue trend
2025 – 2014 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.05B | -$0.39B | -89.41% |
| 2024-12-31 | $0.43B | +$0.37B | +624.05% |
| 2023-12-31 | $0.06B | +$0.03B | +125.73% |
| 2022-12-31 | $0.03B | -$0.00B | -2.84% |
| 2021-12-31 | $0.03B | -$0.00B | -4.44% |
| 2020-12-31 | $0.03B | +$0.03B | +12293.07% |
| 2019-12-31 | $0.00B | -$0.03B | -99.25% |
| 2018-12-31 | $0.03B | +$0.01B | +54.14% |
| 2017-12-31 | $0.02B | +$0.02B | — |
| 2016-12-31 | $0.00B | +$0.00B | — |
Compare revenue vs peers
BiotechnologyCompare PTGX revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Protagonist Therapeutics, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Protagonist Therapeutics, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Protagonist Therapeutics, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
PTGX revenue · 4 questionsPTGX's trailing twelve-month (TTM) revenue is $0.07B. That is a decrease of 89.41% year-over-year from $0.05B in FY2025.
▸ Source: FMP · Protagonist Therapeutics, Inc. SEC filings · GAAP · Protagonist Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026